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Introduction
Intraductal papillary mucinous neoplasms (IPMNs) are a
group of exocrine mucin-producing tumors, diagnosed
at a mean age of 60 years, with a male prevalence [1].
Improvements in imaging techniques have led to an
increasing incidental detection of IPMNs: the prevalence
of incidental cystic pancreatic lesions can be observed in
up to 19.6% of imaging studies [2].
Three types of IPMNs have been described [1]: the
main duct type; the branch-duct type and the mixed
type, which meet the criteria for both MD-IPMN and
BD-IPMN, with significant differences in frequencies of
malignancy in IPMNs according to the morphological




IPMNs appear with a cystic dilation of the involved seg-
ment, either main duct and branch duct. Some findings
can be suggestive of the behavior of the IPMN, accord-
ing to the presence of high risk stigmata or worrisome
features [3].
High risk stigmata suggest the high possibility that the
lesion is malignant, thus requiring resection if the
patient is surgically fit: main duct diameter > 10 mm for
MD-IPMN, the presence of solid enhancing nodules
within the cyst in BD-IPMN, or obstructive jaundice in
presence of a cystic lesion of the pancreatic head.
Worrisome features suggest the possibility that the
lesion could evolve as malignant, thus requiring further
workup by EUS, to better risk-stratify the lesion, and a
strict follow-up: cyst > 3 cm, thickened enhanced cyst
walls, MPD size of 5-9 mm, non-enhancing mural
nodules, abrupt change in the MPD caliber with distal
pancreatic atrophy, and lymphadenopathy.
Imaging features
MR with MRCP has the highest capacity to assess the
presence of communication with main pancreatic duct,
with a sensitivity of 91.4-100% [4].
The proliferating nodule is characterized by the capacity
to enhance after contrast media administration, which can
be appreciated with all imaging technique (CEUS; CT;
MRI), after administration of contrast media.
In case of IPMN, MDCT has a sensitivity of 70% in
the diagnosis of benignity vs malignancy according to
some worrisome features (nodules, main pancreatic duct
> 10 mm, thick septa, calcifications) [5].
MR with MRCP has a sensitivity, specificity and accu-
racy of 70%, 92% and 80%, respectively in the diagnosis of
benignity vs malignancy according to some worrisome fea-
tures (nodules, main pancreatic duct > 10 mm, thick septa,
calcifications)[5].
Management
International consensus guidelines [3] recommend resec-
tion in presence of high-risk stigmata, while in presence of
“worrisome features” the lesion should be evaluated by
EUS to further risk-stratify the lesion. Age, status of the
patient can have influence on the decision management.
Conclusions
Age, clinical, laboratory and imaging findings are accurate
in stratifying these lesions, and imaging plays a pivotal
role in their management.
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